AstraZeneca has been planning to move thousands of employees into a new headquarters for years, but its ongoing construction project has suffered from repeated delays and cost overruns. Now, the company is making moves to sideline its chief contractor to hire another, according to the Construction Enquirer.
The drug giant is in talks to replace Skanska on the project, the publication reports. AstraZeneca declined to comment and Skanska didn’t immediately respond to a request for comment. A source told the Construction Enquirer some of the delay has been caused by a high water table on the site that required “a lot of remedial work,” plus design and other issues.
The move comes after an announcement last year that the HQ and tandem R&D facility will cost more than £500 million, significantly more than the original budget of £330 million. The drugmaker unveiled its HQ plan back in 2013 and hoped to start moving in 2016.
In March, the Cambridge News reported the project isn’t expected to be complete until May 2019. At the time, AstraZeneca and Skanska petitioned for longer working hours because the project suffered from an “overheated” construction market that left them unable to find enough contractors to complete the job on time, according to the report.
Even so, an AZ representative said the drugmaker plans to start a phased move-in by the end of 2018.
Aside from those issues, some excess cost could be attributed to new capabilities added to the R&D labs after the buildings were first conceived, such as robotics, a spokesperson previously told FierceBiotech.
By Eric Sagonowsky
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
